Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Two phase 3, multicenter, randomized, double-blind, placebo-controlled studies

Neil Swanson, Christina Cognata Smith, Mandeep Kaur, Gary Goldenberg

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Two phase 3, multicenter, randomized, double-blind, placebo-controlled studies'. Together they form a unique fingerprint.

Medicine & Life Sciences